EMEA-000268-PIP01-08
Key facts
Active substance |
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/80/2008
|
PIP number |
EMEA-000268-PIP01-08
|
Pharmaceutical form(s) |
Tablet
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
AstraZeneca AB (Sweden)
E-mail: paediatrics@astrazeneca.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|